1Mufson RA. Tumor antigen targets and tumor immunotherapy [J]. Front Biosci, 2006, 11 : 337.
2Kerkela R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate [ J ]. Nat Med, 2006, 12 (8): 908.
3Sohn SK, Kim JG, Kim DH, et al. Cardiac morbidity in advanced chronic myelogenous leukaemia patients treated by successive allogeneic stem cell transplantation with busulphan/cyclophosphamide conditioning after imatinib mesylate administration [J]. Br J Haematol, 2003, 121 (3): 469.
4Rock EP, Goodman V, Jiang JX, et al. Food and drug administration drug approval summary.: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma [J]. Oncologist, 2007, 12 (1): 107.
5Abrams TJ, Murray LJ, Pesenti E, et al. Preelinieal evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer [J]. Mol Cancer Ther, 2003, 2 (10): 1011.
8Escudier B, Eisen T, Stadler WM, et al. Sorafenib in ad- vanced clear - cell renal - cell carcinoma [ J ]. N Engl J Med, 2007, 356 (2): 125.
9Schmidinger M, Zielinski CC, Vogl UM, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma [ J ]. J Clin Oncol, 2008, 26 ( 32 ) : 5204.
10Perez EA, Byme JA, Hammond IW, et al. Results of an analysis of cardiac function in 2, 812 patients treated with lapatinib [J]. J Clin Oncol, 2006, 24 (18S): 583.
5Gordon MS, Margolin K, Talpaz M,et al. Phase I safety and pharmaeokinetic study of recombinant human antivascular endothelial rowth factor in patients with advanced cancer. J Clin Oncol, 2001,19 : 843-850.
6Birnbaum A, Ready N. Gefitinib therapy for non-small cell lung cancer. Curr Treat Options Oncol,2005,6:75-81.
7Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin paclitaxel in pulmonary adenocarcinoma. N Engl J Med,2009,361:947-957.
8Bareschino MA, Schettino C, Troiani T, et al. Erlotinib in cancer treatment. Ann Oncol, 2007,18 Suppl 6: vi35-vi41.
9Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non small cell lung cancer. N Engl J Med,2005,353:123-132.
10Jackman DM, Yeap BY, Lindeman NI,et al. Phase Ⅱ clinical trial of chemotherapy naive patients >or = 70 years of age treated with erlotinib for advanced non small cell lung cancer. J Clin Oncol, 2007,25 : 760-766.
